Sunday, March 16, 2025 | 11:38 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

What's holding coronavirus vaccine front-runner back: A China-Canada spat

Chinese customs hasn't approved shipments of CanSino's vaccine to Canada, the National Research Council of Canada said in an Aug. 26 email\

Coronavirus, vaccine, covid
Premium

Just a few months ago, the Tianjin-based biotechnology firm was positioned at the vanguard of global vaccine trials thanks to a partnership with the Canadian government’s main research agency

Bloomberg
One of the world’s fastest-moving efforts to develop a Covid-19 vaccine is falling behind rivals, its advance appearing to be stymied by political tensions between China and Canada and concerns its shot may not work as well as others.

CanSino Biologics Inc., the Chinese company which in March started the world’s first human tests on an experimental coronavirus shot, has yet to kick off critical final-stage trials on the vaccine it developed with the Chinese military. Meanwhile, rivals like U.S.-based Moderna Inc. and Britain’s AstraZeneca Plc as well as China’s Sinovac Biotech Inc. and Sinopharm are well into this last phase

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in